Scarica l'app Stockscreener
8.04
3.08%
0.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXST Giù?
Forum
Previsione
Precedente Chiudi:
$7.80
Aprire:
$7.81
Volume 24 ore:
509.53K
Relative Volume:
0.54
Capitalizzazione di mercato:
$330.58M
Reddito:
$142.09M
Utile/perdita netta:
$-35.73M
Rapporto P/E:
-9.1551
EPS:
-0.8782
Flusso di cassa netto:
$-22.20M
1 W Prestazione:
-4.17%
1M Prestazione:
-20.47%
6M Prestazione:
-3.25%
1 anno Prestazione:
-74.77%
Intervallo 1D:
$7.81
$8.31
Intervallo di 1 settimana:
$7.65
$8.51
Portata 52W:
$6.32
$32.24
Rxsight Inc Stock (RXST) Company Profile
Nome
Rxsight Inc
Settore
Industria
Telefono
949-521-7822
Indirizzo
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
8.04 | 320.71M | 142.09M | -35.73M | -22.20M | -0.8782 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Iniziato | William Blair | Mkt Perform |
| 2025-07-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Downgrade | Jefferies | Buy → Hold |
| 2025-07-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-09 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Iniziato | Piper Sandler | Neutral |
| 2025-04-09 | Downgrade | UBS | Buy → Neutral |
| 2025-04-04 | Downgrade | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-12-20 | Downgrade | Stifel | Buy → Hold |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-10-29 | Iniziato | Jefferies | Buy |
| 2024-08-20 | Reiterato | Needham | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-05-07 | Reiterato | BTIG Research | Buy |
| 2023-12-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Iniziato | Stifel | Buy |
| 2023-12-04 | Iniziato | Morgan Stanley | Overweight |
| 2023-04-13 | Iniziato | Oppenheimer | Outperform |
| 2022-12-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Iniziato | Needham | Buy |
Mostra tutto
Rxsight Inc Borsa (RXST) Ultime notizie
Can RxSight Inc. reach all time highs this yearIPO Watch & Free Low Drawdown Momentum Trade Ideas - mfd.ru
Options Flow: Will RxSight Inc face regulatory challengesJuly 2025 Action & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Aug Gainers: Will RxSight Inc benefit from AI trendsMarket Risk Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Will RxSight Inc. benefit from geopolitical trendsDividend Hike & Fast Moving Stock Trade Plans - mfd.ru
What’s the RSI of RxSight Inc. stock2025 Market Trends & Weekly Top Gainers Alerts - mfd.ru
RxSight, Inc. to Report Q4 and Full Year 2025 Financial Results on February 25, 2026 - Quiver Quantitative
RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - GlobeNewswire
RxSight, Inc. (RXST) initiated at market perform as firm seeks sales reacceleration - MSN
RxSight, Inc. (RXST) Initiated at Market Perform as Firm Seeks Sales Reacceleration - Insider Monkey
New York State Common Retirement Fund Sells 341,274 Shares of RxSight, Inc. $RXST - MarketBeat
10 Best Long Term Healthcare Stocks to Buy - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against RxSight, Inc. (RXST) And Encourages Investors to Reach Out - accessnewswire.com
The Technical Signals Behind (RXST) That Institutions Follow - Stock Traders Daily
RxSight announces executive leadership reorganization and new appointments - MSN
Performance Recap: Is RxSight Inc in a long term uptrendJuly 2025 Institutional & Long-Term Safe Return Strategies - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Stockholders to Connect - ACCESS Newswire
Brown Capital Management LLC Trims Stock Position in RxSight, Inc. $RXST - MarketBeat
Aug Action: Is RxSight Inc a potential multi baggerShort Setup & Long-Term Safe Investment Plans - baoquankhu1.vn
Aug Big Picture: Will RxSight Inc outperform tech stocksTrade Analysis Report & Low Volatility Stock Recommendations - baoquankhu1.vn
RxSight stock initiated with Market Perform rating by William Blair - Investing.com UK
Needham Lowers Price Target on RxSight to $13 From $14, Keeps Buy Rating - marketscreener.com
William Blair Initiates Coverage on RxSight With Market Perform - marketscreener.com
William Blair Starts RxSight Inc. (RXST) at Market Perform - StreetInsider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Can RxSight Inc. deliver consistent EPS growth2025 Top Gainers & Weekly High Return Forecasts - mfd.ru
RxSight down on CFO transition - MSN
Baillie Gifford & Co. Raises Stock Holdings in RxSight, Inc. $RXST - MarketBeat
RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of "Reduce" by Analysts - MarketBeat
RxSight price target raised to $9 from $8 at JPMorgan - MSN
Precision Trading with Rxsight Inc. (RXST) Risk Zones - Stock Traders Daily
RxSight (NASDAQ:RXST) Trading Down 0.9%Time to Sell? - MarketBeat
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - PR Newswire
Decliners Report: Is RxSight Inc a potential multi bagger2025 Performance Recap & Risk Controlled Daily Trade Plans - baoquankhu1.vn
How Recent Developments Are Shaping The RxSight (RXST) Investment Story - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - ACCESS Newswire
Expert Outlook: RxSight Through The Eyes Of 5 Analysts - Benzinga
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation - accessnewswire.com
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Do Not Use - ocbj.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Institution Moves: What is RxSight Incs valuation compared to sectorTrade Performance Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
RxSight (RXST) soars 14.1%: Is further upside left in the stock? - MSN
RxSight stock price target raised to $11.50 from $11.00 at Jefferies - Investing.com Canada
RxSight stock price target raised to $11.50 from $11.00 at Jefferies By Investing.com - Investing.com South Africa
RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock? - Nasdaq
RxSight Inc. (RXST) PT Raised to $11.50 at Jefferies - StreetInsider
RxSight Shows Growth in Preliminary Q4 and 2025 Results; Names Mark Wilterding as CFO - VisionMonday.com
RxSight Announces New CFO and Strong Preliminary Results - TipRanks
Stifel reiterates Hold rating on RxSight stock amid competition concerns By Investing.com - Investing.com Nigeria
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Rxsight Inc Azioni (RXST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rxsight Inc Azioni (RXST) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Weinberg Eric | See remarks |
Jun 02 '25 |
Option Exercise |
3.93 |
188,002 |
738,848 |
195,351 |
| Thunen Shelley B | See remarks |
Apr 14 '25 |
Option Exercise |
4.34 |
7,792 |
33,806 |
38,354 |
| Fountain Tamara | Director |
Mar 12 '25 |
Sale |
25.71 |
7,000 |
180,002 |
24,793 |
1.33%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):